Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
Year: 2020
Type: article
Source: Blood
Authors: Eytan M. Stein, Stephane De Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L. Liesveld, Rachel J. Cook, Philippe Rousselot, David A Rizzieri, Thorsten Braun, Dale L. Bixby, Gail J. Roboz, Delphine Lebon, Mael Heiblig, Michael J. Kelly, Angela Volkert, Li Zhou, Qing Kang-Fortner, David A. Roth, Pierre Peterlin
Institutions: Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Centre Hospitalier Universitaire de Nice, Hôpital Cardiologique du Haut-Lévêque, University of Rochester Medicine, University of Rochester, OHSU Knight Cancer Institute, Centre Hospitalier de Versailles, Duke University, Hôpital Avicenne, University of Michigan, Cornell University, Weill Cornell Medical Center, Centre Hospitalier Universitaire Amiens-Picardie, Hôpital Lyon Sud, Syros Pharmaceuticals (United States), Centre Hospitalier Universitaire de Nantes
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3095938527